medigraphic.com
ISSN 1561-3038 (Print)

2016, Number 3

<< Back Next >>

Rev Cubana Med Gen Integr 2016; 32 (3)

Adherence to treatment in rheumatoid arthritis: an essential condition for disease control

Ruiz MC, Parada PAM, Urrego VA, Gallego GD

Language: Spanish
References: 50
Page: 1-13
PDF size: 116.24 Kb.


ABSTRACT

Introduction: Rheumatoid arthritis is the most common inflammatory arthritis in adults and in many cases leads to work disability, which has a dramatic impact on the daily lives of the individuals suffering this disease. The main objective of the treatment is to reduce inflammatory activity and progression of the disease, however, the therapy is based on antirheumatic agents with many side effects and dosing schedules difficult to understand; this circumstances may be associated low adhesion to therapy. Objective: To cover general aspects of the treatment of rheumatoid arthritis and the impact of adherence to it. Methods: Recently published and relevant articles were used for this review; the databases used were PubMed, Scielo and LILACS. Conclusions: Most publications available in the literature showed low compliance with treatment regimens in patients with rheumatoid arthritis, this was associated with greater progression of disease and adverse clinical outcomes; therefore, it is essential to design strategies that aim to increase adherence to recommended treatment schemes.


REFERENCES

  1. Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. Etanercept- Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2015 ;67(12):1656-63.

  2. Firestein GS. Etiology and Pathogenesis of Rheumatoid Arthritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes LB, O'Dell JR. eds. Kelley's Textbook of Rheumatology, 9e. Philadelphia, PA: Elsevier Saunders; 2013.

  3. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1-26.

  4. Tambar S, Ruderman EM. Current management of rheumatoid arthritis. Manag Care Interface. 2007;20(7):18-24.

  5. Mora KC, González A, Quintana LG. Guía de tratamiento de la artritis reumatoide temprana en un Hospital Universitario de Colombia. Rev.Colomb.Reumatol. 2008; 15(2):79-91.

  6. Verhoeven F, Tordi N, Prati C, Demougeot C, Mougin F, Wendling D. Physical activity in patients with rheumatoid arthritis. Joint Bone Spine. 2015 Nov 27. pii: S1297-319X(15)00239-0.

  7. Vega J, Pinto LF, Muñoz C, Márquez JD, Rodríguez LB, Velásquez CJ. Infecciones en pacientes con artritis reumatoide: medicamentos moduladores de la respuesta biológica versus fármacos modificadores de la enfermedad. Seguimiento a un año. Rev Colomb Reumatol. 2013;21(1):27-34.

  8. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007;21(1):27-42.

  9. Noa M, Mas R, Mendoza S, Valle M. Fisiopatología, tratamiento y modelos experimentales de artritis reumatoide. Rev Cubana Farm. 2011;45(2):297-308.

  10. Botello D, Rojas A, Calderón R, Cruz P, Amaya JC, Calixto OJ, et al. Autoclinimetría aplicada colectivamente en pacientes latinoamericanos con artritis reumatoide. Colegio Mayor de Nuestra Señora del Rosario: Universidad CES; 2012.

  11. Jawaheer D, Lumm RF, Gregersen PK, Criswell LA. Influence of Male Sex on disease Phenotype in Familial Rheumatoid. Arthritis Rheum. 2006;54(10):3087-94.

  12. Muñetón GA, Quintana LG. La epidemiología de la artritis reumatoide. Rev.Colomb.Reumatol. 2015:22(3):145-7.

  13. Gutiérrez WA, Samudio ML, Fernández DG, Díaz MC, Gutiérrez JM. Artritis reumatoide en el anciano. Revisión narrativa. Rev.Colomb.Reumatol. 2013;20(2):91- 101.

  14. Delgado-AM, Martín J, Granados J, Anaya JM. Epidemiología genética de la artritis reumatoide: ¿qué esperar de América Latina? Biomédica. 2006;26:562-84.

  15. Karlson EW, Deane K. Environmental and Gene-Environment Interactions and Risk of Rheumatoid Arthritis. Rheum Dis Clin North Am. 2012;38(2):405-26.

  16. Fisher BA, Cartwright AJ, Quirke AM, de Pablo P, Romaguera D, Panico S, et al. Smoking, Porphyromonas gingivalis and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case-control study. BMC Musculoskelet Disord. 2015;16(1):331.

  17. Franco-Aguirre JQ, Cardona-Arias J. Calidad de vida relacionada con la salud en personas con artritis reumatoide: caracterización de los estudios publicados entre 2003-2013. Iatreia. 2015;28(2):109-19.

  18. Ariza R, van Walsem A, Canal C, Roldán C, Betegón L, Oyagüez I, et al. Análisis de minimización de costes de abatacept subcutáneoen el tratamiento de la artritis reumatoide en España. Farm Hosp. 2014;38(4):257-65.

  19. Chaparro R, Rillo OL, Benegas M, Correa MA, Citera G, Maldonado JA, et al. Adherencia al tratamiento de pacientes con artritis reumatoidea que reciben medicamentos biológicos. Rev Arg Reumatol. 2013;24(4):18-26.

  20. Zwikker H, van den Bemt B, van den Ende C, van Lankveld W, den Broeder A, van den Hoogen F, et al. Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. Patient Educ Couns. 2012;89(1):143-51.

  21. Fernández A, Pérez N, Piñeiro S, López I, López V. Terapias biológicas en artritis reumatoide: análisis del coste de las alternativas terapéuticas. Galicia Clin. 2012;73 (4):143-46.

  22. Tribiño G. Prescripción de medicamentos en pacientes con artritis reumatoide atendidos en una IPS de Bogotá: caracterización y evaluación de cumplimiento con indicadores de calidad [tesis]. Bogotá: Pontificia Universidad Javeriana; 2014.

  23. Álvaro-Gracia JM, Fernández-Nebro A, García-López A, Guzmán M, Blanco FJ, Navarro FJ, et al. Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: subanálisis de los datos españoles de un estudio abierto cercano a la práctica clínica habitual. Reumatol Clin. 2014;10(2):94-100.

  24. Cano L. Efectividad de un programa educacional multidisciplinar estandarizado en enfermos con artritis reumatoide, lupus eritematoso sistémico y espondilitis anquilosante [tesis]. Málaga: Universidad de Málaga; 2014.

  25. Longo UG, Petrillo S, Denaro V. Current Concepts in the Management of Rheumatoid Hand. Int J Rheumatol. 2015;2015:648073.

  26. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061-75.

  27. Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, et al. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol Clin. 2015;11(5):279-94.

  28. Román JA, Ivorra J, Monte-Boquet E, Canal C, Oyagüez I, Gómez-Barrera M. Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight. Reumatol Clin. 2015;pii:S1699-258X(15)00144-8.

  29. Díaz-Coto JF, Monge-Zeledón P, Avilés-Montoya E, Sáenz-Castro R. Drogas Modi cadoras de la Artritis Reumatoide (DMAR). Acta méd costarric. 2011;53(1):10-13.

  30. Tornero J, Ballina FJ, Calvo J, Caracuel MA, Carbonell J, López A. Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración. Reumatol Clin. 2015;11(1):3-8.

  31. Singh JA, Wells GA, Christensen R, Tanjong E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.

  32. Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health. 2013;16(2):385-93.

  33. Sántos-Moreno P, Jannaut MJ, Sánchez G, Caballero C, Rodríguez I. Evaluación de la implementación de la estrategia "Tratamientos por objetivos" en pacientes con artritis reumatoide en 8 centros de reumatología en Colombia después de un programa integral de difusión entre médicos. Rev Med Panama. 2014;34(3):2-7.

  34. Pasma A, van't Spijker A, Hazes JM, Busschbach JJ, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43(1):18-28.

  35. Van den Bemt BJ, Van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, Van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009;36(10):2164-70.

  36. Van Mierlo T, Fournier R, Ingham M. Targeting Medication Non-Adherence Behavior in Selected Autoimmune Diseases: A Systematic Approach to Digital Health Program Development. PLoS One. 2015;10(6):e0129364.

  37. Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, et al. The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology (Oxford). 2015;54(10):1780-91.

  38. Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford). 2015;54(3):494-9.

  39. Hughes LD, Done J, Young A. A 5 item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs. BMC Musculoskelet Disord. 2013;14:286.

  40. Quintana G, Restrepo JP, Cáceres H, Rueda JD, Rosselli D. Evaluación económica del tratamiento de artritis reumatoide con terapia biológica anti TNF en Colombia. Acta Med Colomb. 2011;36(1):24-9.

  41. Montoya N, Gómez L, Vélez M, Rosselli D. Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia. Rev.Colomb.Reumatol. 2011;18(1):26-33.

  42. Iannone F, Notarnicola A, Lopalco G, Lapadula G. Different switching rate of anti- TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. Joint Bone Spine. 2014;81(5):458-9.

  43. Hidalgo A, Villoro R, Ivanova A, Morell A, Talavera P, Ferro B. Tratamiento biológico de la artritis reumatoide en España. Análisis de impacto presupuestario de la utilización de certolizumab pegol. Pharmacoecon Span Res Artic. 2014;11:97-107.

  44. Bliddal H, Eriksen SA, Christensen R, Lorenzen T, Hansen MS, Østergaard M, et al. Adherence to methotrexate in rheumatoid arthritis: a danish nationwide cohort study. Arthritis. 2015;2015:915142.

  45. Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, et al. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. J Manag Care Spec Pharm. 2015;21(4):318-29.

  46. Román JA, Ivorra J, Monte-Boquet E, Canal C, Oyagüez I, Gómez-Barrera M. Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight. Reumatol Clin. 2015; pii:S1699-258X(15)00144-8.

  47. Joplin S, van der Zwan R, Joshua F, Wong PK. Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int. 2015;2015:150658.

  48. Zwikker HE, van den Ende CH, van Lankveld WG, den Broeder AA, van den Hoogen FH, van de Mosselaar B, et al. Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: a randomized controlled trial. Patient Educ Couns. 2014;94(3):356-61.

  49. Ferguson A, Ibrahim FA, Thomas V, Weinman J, Simpson C, Cope AP, et al. Improving medication adherence in rheumatoid arthritis (RA): a pilotstudy. Psychol Health Med. 2015;20(7):781-9.

  50. Adams RJ. Improving health outcomes with better patient understanding and education. Risk Manag Healthc Policy. 2010;3:61-72.




2020     |     www.medigraphic.com